The Pharmacodynamic Impact of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, on Circulating Levels of Inflammatory Biomarkers in Patients with Psoriatic Arthritis: Substudy Results from a Phase III, Randomized, Placebo-Controlled Trial (PALACE 1)

Figure 2

Changes in biomarkers with placebo, apremilast 20 mg BID, and apremilast 30 mg BID over Weeks 0 to 24. versus placebo (rank analysis of covariance two-sided value). . SEM: standard error mean.

(a) Week 4 (observed data)

(b) Week 16 (LOCF)

(c) Week 24 (LOCF)